Figure 1From: Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide Summary of Patient Disposition. Of 18 patients enrolled, 3 withdrew before receiving any chemotherapy and 15 received at least 1 chemotherapy dose (safety population). Of these 15 patients, 3 withdrew before receiving a first dose of eltrombopag during Cycle 2. Seven, 4, and 1 patients received at least 1 dose of 75 mg, 100 mg, and 150 mg eltrombopag, respectively.Back to article page